Pfizer (PFE) reported Q4 FY 2017 earnings of $0.62 per share (versus $0.47 in Q4 FY 2016), beating analysts' consensus estimate of $0.56.
The company's quarterly revenues amounted to $13.703 bln (+0.6% y/y), generally in-line with analysts' consensus estimate of $13.675 bln.
The company also issued upside guidance for FY 2018, projecting EPS of $2.90-3.00 (versus analysts' consensus estimate of $2.78) at revenues of $53.5-55.5 bln (versus analysts' consensus estimate of $53.82 bln).
PFE fell to $38.90 (-0.31%) in pre-market trading.